Presented at ASH: the EPCORE FL-1 study on epcoritamab in follicular lymphoma
Franck Morschhauser joins Ben Abbott of The Lancet to discuss the phase 3 EPCORE FL-1 study on epcoritamab, lenalidomide, and rituximab for relapsed or refractory follicular lymphoma, which is being presented at ASH 2025. Click here to read the full article: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02360-8/fulltext Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from The Lancet in conversation with
Can semaglutide be used to treat alcohol use disorder?
Louise Chappell and Na’ama Carlin on Personal Cancer Stories
Susannah Stanway on the London Global Cancer Week
Carlos Monteiro, Camila Corvalán, and Phil Baker on Ultra-Processed Foods and Human Health
Get summaries like this every morning.
Free AI-powered recaps of The Lancet in conversation with and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.